CN105497053B - 可利霉素在抗结核分枝杆菌感染中的应用 - Google Patents
可利霉素在抗结核分枝杆菌感染中的应用 Download PDFInfo
- Publication number
- CN105497053B CN105497053B CN201511030787.7A CN201511030787A CN105497053B CN 105497053 B CN105497053 B CN 105497053B CN 201511030787 A CN201511030787 A CN 201511030787A CN 105497053 B CN105497053 B CN 105497053B
- Authority
- CN
- China
- Prior art keywords
- rokitamycin
- mycobacterium tuberculosis
- clinical
- application
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511030787.7A CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
EP16880885.5A EP3384915B1 (en) | 2015-12-31 | 2016-12-05 | Carrimycin for the treatment of mycobacterium tuberculosis infections |
KR1020187021578A KR20180098624A (ko) | 2015-12-31 | 2016-12-05 | 결핵균 마이코박테리움 터버큘로시스(Mycobacterium tuberculosis) 감염 저항성에서의 켈리마이신의 응용 |
US16/067,327 US11000708B2 (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in Mycobacterium tuberculosis infection resistance |
DK16880885.5T DK3384915T3 (en) | 2015-12-31 | 2016-12-05 | Carrimycin til behandling af mycobacterium tuberculosis-infektioner |
PL16880885T PL3384915T3 (pl) | 2015-12-31 | 2016-12-05 | Karymycyna do leczenia zakażeń prątkiem gruźlicy |
PE2018001212A PE20190210A1 (es) | 2015-12-31 | 2016-12-05 | Aplicaciones de carrimicina en la infeccion por micobacterium tuberculosis resistente |
AU2016382584A AU2016382584B2 (en) | 2015-12-31 | 2016-12-05 | Applications of kelimycin in mycobacterium tuberculosis infection resistance |
PCT/CN2016/108502 WO2017114095A1 (zh) | 2015-12-31 | 2016-12-05 | 可利霉素在抗结核分枝杆菌感染中的应用 |
BR112018013327-2A BR112018013327A2 (zh) | 2015-12-31 | 2016-12-05 | Application of Rimycin in Anti - tuberculosis Mycobacterium Infection |
MYPI2018001121A MY191800A (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
JP2018553283A JP6770584B2 (ja) | 2015-12-31 | 2016-12-05 | 抗結核感染におけるカリマイシン(Kelimycin)の応用 |
UAA201808048A UA121159C2 (uk) | 2015-12-31 | 2016-12-05 | Застосування кариміцину при стійкості інфекції мycobacterium tuberculosis |
RU2018125622A RU2733382C2 (ru) | 2015-12-31 | 2016-12-05 | Способ применения карримицина против резистентности инфекции, спровоцированной микобактерией туберкулеза |
ES16880885T ES2785644T3 (es) | 2015-12-31 | 2016-12-05 | Carrimicina para el tratamiento de infecciones por Mycobacterium tuberculosis |
CA3010020A CA3010020A1 (en) | 2015-12-31 | 2016-12-05 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
PH12018501394A PH12018501394A1 (en) | 2015-12-31 | 2018-06-28 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
ZA2018/04398A ZA201804398B (en) | 2015-12-31 | 2018-06-29 | Use of carrimycin in mycobacterium tuberculosis infection resistance |
CL2018001804A CL2018001804A1 (es) | 2015-12-31 | 2018-06-29 | Uso de la carrimicina en la infección por micobacterium tuberculosis resistente |
CONC2018/0007133A CO2018007133A2 (es) | 2015-12-31 | 2018-07-09 | Uso de la carrimicina en la infección por micobacterium tuberculosis resistente |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511030787.7A CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105497053A CN105497053A (zh) | 2016-04-20 |
CN105497053B true CN105497053B (zh) | 2018-02-13 |
Family
ID=55705614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511030787.7A Active CN105497053B (zh) | 2015-12-31 | 2015-12-31 | 可利霉素在抗结核分枝杆菌感染中的应用 |
Country Status (20)
Country | Link |
---|---|
US (1) | US11000708B2 (zh) |
EP (1) | EP3384915B1 (zh) |
JP (1) | JP6770584B2 (zh) |
KR (1) | KR20180098624A (zh) |
CN (1) | CN105497053B (zh) |
AU (1) | AU2016382584B2 (zh) |
BR (1) | BR112018013327A2 (zh) |
CA (1) | CA3010020A1 (zh) |
CL (1) | CL2018001804A1 (zh) |
CO (1) | CO2018007133A2 (zh) |
DK (1) | DK3384915T3 (zh) |
ES (1) | ES2785644T3 (zh) |
MY (1) | MY191800A (zh) |
PE (1) | PE20190210A1 (zh) |
PH (1) | PH12018501394A1 (zh) |
PL (1) | PL3384915T3 (zh) |
RU (1) | RU2733382C2 (zh) |
UA (1) | UA121159C2 (zh) |
WO (1) | WO2017114095A1 (zh) |
ZA (1) | ZA201804398B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497053B (zh) | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
AU2018247555B2 (en) * | 2017-04-06 | 2024-04-18 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin and pharmaceutically acceptable salt thereof for manufacture of medicament for treatment and/or prevention of tumors |
CN110384710B (zh) * | 2018-04-17 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
CN110384802B (zh) * | 2018-04-17 | 2021-09-17 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
WO2021219112A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用 |
CN113577086B (zh) * | 2020-04-30 | 2023-05-02 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
WO2022119899A1 (en) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1554355A (zh) * | 2003-12-23 | 2004-12-15 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
WO2007065637A1 (de) * | 2005-12-06 | 2007-06-14 | Andreas Kern | Oral einzunehmende antibiotika zur behandlung von hämorrhoidenleiden |
WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2126108B1 (zh) * | 1971-02-25 | 1974-08-02 | Rhone Poulenc Sa | |
US7098219B2 (en) * | 2000-08-01 | 2006-08-29 | Wockhart Limited | Inhibitors of cellular efflux pumps of microbes |
US20080161249A1 (en) * | 2004-11-17 | 2008-07-03 | Smithkline Beecham Corporation | Use of Novel Antibacterial Compounds |
US9089586B2 (en) * | 2010-05-25 | 2015-07-28 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
US8778896B2 (en) * | 2010-05-25 | 2014-07-15 | Shenyang Tonglian Group Co., Ltd. | Levoisovalerylspiramycin I, II or III, preparations, preparation methods and uses thereof |
JP6116206B2 (ja) | 2012-11-26 | 2017-04-19 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
CN105497053B (zh) * | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
-
2015
- 2015-12-31 CN CN201511030787.7A patent/CN105497053B/zh active Active
-
2016
- 2016-12-05 WO PCT/CN2016/108502 patent/WO2017114095A1/zh active Application Filing
- 2016-12-05 AU AU2016382584A patent/AU2016382584B2/en active Active
- 2016-12-05 US US16/067,327 patent/US11000708B2/en active Active
- 2016-12-05 CA CA3010020A patent/CA3010020A1/en active Pending
- 2016-12-05 KR KR1020187021578A patent/KR20180098624A/ko active Search and Examination
- 2016-12-05 MY MYPI2018001121A patent/MY191800A/en unknown
- 2016-12-05 PL PL16880885T patent/PL3384915T3/pl unknown
- 2016-12-05 UA UAA201808048A patent/UA121159C2/uk unknown
- 2016-12-05 JP JP2018553283A patent/JP6770584B2/ja active Active
- 2016-12-05 RU RU2018125622A patent/RU2733382C2/ru active
- 2016-12-05 PE PE2018001212A patent/PE20190210A1/es unknown
- 2016-12-05 DK DK16880885.5T patent/DK3384915T3/da active
- 2016-12-05 BR BR112018013327-2A patent/BR112018013327A2/zh active Search and Examination
- 2016-12-05 EP EP16880885.5A patent/EP3384915B1/en active Active
- 2016-12-05 ES ES16880885T patent/ES2785644T3/es active Active
-
2018
- 2018-06-28 PH PH12018501394A patent/PH12018501394A1/en unknown
- 2018-06-29 CL CL2018001804A patent/CL2018001804A1/es unknown
- 2018-06-29 ZA ZA2018/04398A patent/ZA201804398B/en unknown
- 2018-07-09 CO CONC2018/0007133A patent/CO2018007133A2/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1554355A (zh) * | 2003-12-23 | 2004-12-15 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
WO2007065637A1 (de) * | 2005-12-06 | 2007-06-14 | Andreas Kern | Oral einzunehmende antibiotika zur behandlung von hämorrhoidenleiden |
WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
CN103142520A (zh) * | 2013-03-15 | 2013-06-12 | 沈阳同联集团有限公司 | 一种可利霉素片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis;FALZARI Kanakeshwari等;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;20050430;第49卷(第4期);第1447-1454页 * |
新一代必特螺旋霉素基因工程菌的微波诱变;戴剑漉等;《中国抗生素杂志》;20090731;第34卷(第7期);第406-410页,428页 * |
Also Published As
Publication number | Publication date |
---|---|
CA3010020A1 (en) | 2017-07-06 |
BR112018013327A2 (zh) | 2018-12-04 |
RU2018125622A3 (zh) | 2020-03-26 |
KR20180098624A (ko) | 2018-09-04 |
CN105497053A (zh) | 2016-04-20 |
ES2785644T3 (es) | 2020-10-07 |
CO2018007133A2 (es) | 2018-07-19 |
JP6770584B2 (ja) | 2020-10-14 |
WO2017114095A1 (zh) | 2017-07-06 |
JP2019501220A (ja) | 2019-01-17 |
PH12018501394A1 (en) | 2019-02-27 |
EP3384915B1 (en) | 2020-02-19 |
EP3384915A1 (en) | 2018-10-10 |
RU2733382C2 (ru) | 2020-10-01 |
CL2018001804A1 (es) | 2018-09-28 |
RU2018125622A (ru) | 2020-01-31 |
PL3384915T3 (pl) | 2020-09-07 |
US20190001160A1 (en) | 2019-01-03 |
EP3384915A4 (en) | 2018-12-19 |
AU2016382584A1 (en) | 2018-07-26 |
US11000708B2 (en) | 2021-05-11 |
ZA201804398B (en) | 2019-09-25 |
MY191800A (en) | 2022-07-15 |
AU2016382584B2 (en) | 2022-01-06 |
PE20190210A1 (es) | 2019-02-07 |
DK3384915T3 (en) | 2020-05-04 |
UA121159C2 (uk) | 2020-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105497053B (zh) | 可利霉素在抗结核分枝杆菌感染中的应用 | |
Garg et al. | Ciprofloxacin-resistant Pseudomonas keratitis | |
Silcox et al. | Identification of clinically significant Mycobacterium fortuitum complex isolates | |
Casemore | Sensitivity of Hartmannella (Acanthamoeba) to 5-fluorocytosine, hydroxystilbamidine, and other substances | |
CN111789831B (zh) | 苯乙肼在制备抗脓肿分枝杆菌感染的药物中的应用 | |
CN106619829A (zh) | 一种抗金黄色葡萄球菌的药物及制备方法和用途 | |
CN115364107B (zh) | 石胆酸的用途 | |
CN101857893B (zh) | 一种细菌群相同步培养的方法及试剂盒 | |
Mahendranathan et al. | Efficacy of different solvent extracts from the aerial parts of Costus speciosus (Koen.) for the potential antibacterial activity against selected human pathogenic bacteria | |
CN109925503A (zh) | 一种逆转金黄色葡萄球菌耐药性的中药注射剂 | |
CN108310393A (zh) | 一种利福霉素-喹嗪酮偶联分子的应用 | |
CN102229898B (zh) | 用于治疗菌群失调症菌群紊乱症的大肠埃希氏菌、制剂及其制备方法 | |
Jha et al. | A comparative assessment of Petroff’s and n-acetyl-l-cysteine-sodium hydroxide method in the diagnosis of pulmonary tuberculosis | |
Taghizadeh et al. | Antimicrobial activity of different honey samples against Pseudomonas aeruginosa in vitro | |
CN103122368B (zh) | 一种喹喔啉类化合物作为抗结核分枝杆菌抑制剂的应用 | |
Abbas et al. | Isolation and Screening of Actinomycetes producing Antibacterial compounds from different river sediments | |
Khursheed et al. | Anti-Biofilm Forming Activity of Natural Products Extract Punica Granatum L. and Magnifera Indica L | |
CN108159039A (zh) | 一种可用于制备抗结核病药物的化合物 | |
Devaraj et al. | EFFICACY OF AQUEOUS EXTRACT OF KAMPILLAKA (MALLOTUS PHILIPPENSIS) AGAINST PATHOGENIC BACTERIA FROM DUSHTAVRANA (NON-HEALING ULCER) | |
AA et al. | The Antimycobacterial Effect of Honey: An In-Vitro Study. | |
CN117398430A (zh) | 鸡矢藤和含鸡矢藤提取物的组合物及其应用 | |
CN103122367B (zh) | 一种吡啶类化合物作为抗结核分枝杆菌抑制剂的应用 | |
CN103122369B (zh) | 一种叠氮噻吩类化合物作为抗结核分枝杆菌抑制剂的应用 | |
Tefera et al. | In vitro anti-Neisseria gonorrhoeae activity of Albizia gummifera and | |
CN102974217A (zh) | 一种用于蛋白、血清溶液的除菌和净化的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170804 Address after: Shenbei New Area yaoyang road Shenyang City, Liaoning province 110164 No. 18-12 Applicant after: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 110042 Liaoning Province, Shenyang City District East Shuncheng Street Yucai Lane No. 18 Applicant before: SHENYANG TONGLIAN GROUP Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200520 Address after: 201612 No.55, Xinfei Road, Songjiang District, Shanghai Patentee after: SHANGHAI TONGLIAN PHARMACEUTICAL Co.,Ltd. Address before: Shenbei New Area yaoyang road Shenyang City, Liaoning province 110164 No. 18-12 Patentee before: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of karimycin in anti-mycobacterium tuberculosis infection Effective date of registration: 20220829 Granted publication date: 20180213 Pledgee: Shengjing bank Yingkou branch of Limited by Share Ltd. Pledgor: SHANGHAI TONGLIAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2022210000135 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |